People
Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical officer
23 September 2021 - - US-based precision medicine company Endeavor BioMedicines has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis, the compan...
ImmunoGen Names Thackray, MD to its Board of Directors
22 September 2021 - - US-based ImmunoGen Inc. (NASDAQ: IMGN), a specialist in the field of antibody-drug conjugates for the treatment of cancer, has appointed Helen M. Thackray, MD, FAAP to its b...
Aerie Pharmaceuticals Names Interim Executive Chair as Chairman, CEO Anido Departs
22 September 2021 - - US-based ophthalmic pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is executing its succession plan for its long-serving chairman and CEO and that effective Se...
Eiger BioPharmaceuticals names new general counsel and chief compliance officer
22 September 2021 - Eiger BioPharmaceuticals Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company, announced on Tuesday that it has named Erik Atkisson as its new general counsel and chief ...
Fusion Pharmaceuticals names new SVP, business development
22 September 2021 - Fusion Pharmaceuticals Inc (Nasdaq: FUSN), a clinical-stage oncology company, announced on Tuesday that it has named Eric S Hoffman, PhD as its new senior vice president, business ...
HUYABIO International treats first patient in trial of HBI-8000 combined with Bristol Myers Squibb's Opdivo
22 September 2021 - HUYABIO International, a global developer of novel biopharmaceutical product opportunities originating in China, announced on Tuesday that it has treated its first patient in a piv...